134 related articles for article (PubMed ID: 11128640)
1. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.
Tamamura H; Omagari A; Oishi S; Kanamoto T; Yamamoto N; Peiper SC; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem Lett; 2000 Dec; 10(23):2633-7. PubMed ID: 11128640
[TBL] [Abstract][Full Text] [Related]
2. Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.
Tamamura H; Omagari A; Hiramatsu K; Gotoh K; Kanamoto T; Xu Y; Kodama E; Matsuoka M; Hattori T; Yamamoto N; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem Lett; 2001 Jul; 11(14):1897-902. PubMed ID: 11459656
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.
Tamamura H; Imai M; Ishihara T; Masuda M; Funakoshi H; Oyake H; Murakami T; Arakaki R; Nakashima H; Otaka A; Ibuka T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Bioorg Med Chem; 1998 Jul; 6(7):1033-41. PubMed ID: 9730240
[TBL] [Abstract][Full Text] [Related]
4. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
[TBL] [Abstract][Full Text] [Related]
5. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
6. Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).
Tamamura H; Arakaki R; Funakoshi H; Imai M; Otaka A; Ibuka T; Nakashima H; Murakami T; Waki M; Matsumoto A; Yamamoto N; Fujii N
Bioorg Med Chem; 1998 Feb; 6(2):231-8. PubMed ID: 9547946
[TBL] [Abstract][Full Text] [Related]
7. Conformational study of a highly specific CXCR4 inhibitor, T140, disclosing the close proximity of its intrinsic pharmacophores associated with strong anti-HIV activity.
Tamamura H; Sugioka M; Odagaki Y; Omagari A; Kan Y; Oishi S; Nakashima H; Yamamoto N; Peiper SC; Hamanaka N; Otaka A; Fujii N
Bioorg Med Chem Lett; 2001 Feb; 11(3):359-62. PubMed ID: 11212110
[TBL] [Abstract][Full Text] [Related]
8. Certification of the critical importance of L-3-(2-naphthyl)alanine at position 3 of a specific CXCR4 inhibitor, T140, leads to an exploratory performance of its downsizing study.
Tamamura H; Omagari A; Hiramatsu K; Oishi S; Habashita H; Kanamoto T; Gotoh K; Yamamoto N; Nakashima H; Otaka A; Fujii N
Bioorg Med Chem; 2002 May; 10(5):1417-26. PubMed ID: 11886804
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives.
Tamamura H; Hiramatsu K; Kusano aS; Terakubo S; Yamamoto N; Trent JO; Wang Z; Peiper SC; Nakashima H; Otaka A; Fujii N
Org Biomol Chem; 2003 Nov; 1(21):3656-62. PubMed ID: 14649896
[TBL] [Abstract][Full Text] [Related]
10. Downsizing of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II), with the maintenance of anti-HIV activity and solution structure.
Tamamura H; Waki M; Imai M; Otaka A; Ibuka T; Waki K; Miyamoto K; Matsumoto A; Murakami T; Nakashima H; Yamamoto N; Fujii N
Bioorg Med Chem; 1998 Apr; 6(4):473-9. PubMed ID: 9597190
[TBL] [Abstract][Full Text] [Related]
11. [Development of selective antagonists against an HIV second receptor].
Tamamura H
Yakugaku Zasshi; 2001 Nov; 121(11):781-92. PubMed ID: 11725546
[TBL] [Abstract][Full Text] [Related]
12. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection.
Murakami T; Nakajima T; Koyanagi Y; Tachibana K; Fujii N; Tamamura H; Yoshida N; Waki M; Matsumoto A; Yoshie O; Kishimoto T; Yamamoto N; Nagasawa T
J Exp Med; 1997 Oct; 186(8):1389-93. PubMed ID: 9334379
[TBL] [Abstract][Full Text] [Related]
13. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.
Arakaki R; Tamamura H; Premanathan M; Kanbara K; Ramanan S; Mochizuki K; Baba M; Fujii N; Nakashima H
J Virol; 1999 Feb; 73(2):1719-23. PubMed ID: 9882387
[TBL] [Abstract][Full Text] [Related]
14. [A study of anti-HIV compounds which interfere the virus entry via coreceptor CXCR4].
Kanbara K; Fujii N; Nakashima H
Kansenshogaku Zasshi; 2000 Mar; 74(3):237-44. PubMed ID: 10783578
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.
Tamamura H; Hiramatsu K; Miyamoto K; Omagari A; Oishi S; Nakashima H; Yamamoto N; Kuroda Y; Nakagawa T; Otaka A; Fujii N
Bioorg Med Chem Lett; 2002 Mar; 12(6):923-8. PubMed ID: 11958995
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the T140-based pharmacophores leads to the development of more potent and bio-stable CXCR4 antagonists.
Tamamura H; Hiramatsu K; Mizumoto M; Ueda S; Kusano S; Terakubo S; Akamatsu M; Yamamoto N; Trent JO; Wang Z; Peiper SC; Nakashima H; Otaka A; Fujii N
Org Biomol Chem; 2003 Nov; 1(21):3663-9. PubMed ID: 14649897
[TBL] [Abstract][Full Text] [Related]
17. Pharmacophore-based small molecule CXCR4 ligands.
Narumi T; Tanaka T; Hashimoto C; Nomura W; Aikawa H; Sohma A; Itotani K; Kawamata M; Murakami T; Yamamoto N; Tamamura H
Bioorg Med Chem Lett; 2012 Jun; 22(12):4169-72. PubMed ID: 22579418
[TBL] [Abstract][Full Text] [Related]
18. Peptide-lead CXCR4 antagonists with high anti-HIV activity.
Fujii N; Tamamura H
Curr Opin Investig Drugs; 2001 Sep; 2(9):1198-202. PubMed ID: 11717804
[TBL] [Abstract][Full Text] [Related]
19. Paradoxical downregulation of CXC chemokine receptor 4 induced by polyphemusin II-derived antagonists.
Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Yano Y; Matsuzaki K; Navenot JM; Peiper SC; Fujii N
Bioconjug Chem; 2012 Jun; 23(6):1259-65. PubMed ID: 22486464
[TBL] [Abstract][Full Text] [Related]
20. An antiparallel beta-sheet and a beta-turn characterize the structure of antiviral HIV-1 peptide T140, as revealed by 2D NMR and MD Simulations.
Tauro S; Coutinho E; Srivastava S
Protein Pept Lett; 2003 Aug; 10(4):346-60. PubMed ID: 14529488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
